| Biomarker ID | 853 |
| PMID | 22298030 |
| Year | 2012 |
| Biomarker | miR-30c |
| Biomarker Basis | Expression Based |
| Biomolecule | miRNA |
| Source | Plasma |
| Subjects | Humans |
| Regulation | Downregulated in PCa |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include(miR-30c):- regulation of transcription by RNA polymerase II; Gene expression (Transcription); cellular protein modification process; Protein modification process; cellular metabolic process |
| Experiment | prostate cancer Vs benign prostatic hyperplasia |
| Type of Biomarker | Diagnostic |
| Cohort | Training set: 25 patients with prostate cancer, 17 with Benign prostatic hyperplasia. Validation Set: 80 CaP, 44 BPH, and 54 healthy controls |
| Senstivity | 79.63% |
| Specificity | 68.75% |
| AUC | 0.818 (95% CI: 0.749–0.887) |
| Accuracy | NA |
| Level Of Significance | Training: p<0.0001 |
| Method Used | Training Set: Microarrays, Validation set; qRT-PCR |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on Independent Patient Cohort |
| Technical Name | miR-30c |